Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 1, pp 225–226 | Cite as

Sandostatin desensitization–a strategy useful for patients with carcinoid tumors, intolerant to sandostatin

Original Article
  • 72 Downloads

Abstract

Sandostatin immediate release (IR) is frequently used to treat patients with carcinoid tumors. However, some patients are unable to tolerate the immediate side effects of sandostatin IR leading to discontinuation of the drug. There is no literature available to guide the management of patients’ sensitivity/intolerance to sandostatin IR. We report a 49-year-old male with carcinoid tumor who was intolerant to sandostatin IR initially but was able to tolerate the drug after we employed a desensitization strategy.

Keywords

Carcinoid Sandostatin Long-acting sandostatin Depot preparation 

References

  1. 1.
    Rubin J, Ajani J, Schirmer W et al (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17(2):600–606PubMedGoogle Scholar
  2. 2.
    Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20(3):157–198PubMedCrossRefGoogle Scholar
  3. 3.
    Krulich L, Dhariwal AP, McCann SM (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83(4):783–790PubMedCrossRefGoogle Scholar
  4. 4.
    Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334(4):246–254PubMedCrossRefGoogle Scholar
  5. 5.
    Bauer W, Briner U, Doepfner W et al (1982) SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31(11):1133–1140PubMedCrossRefGoogle Scholar
  6. 6.
    Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15(6):966–973PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of OncologyInnovis HealthFargoUSA
  2. 2.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations